Stocks of Akari Therapeutics Plc (NASDAQ:AKTX) traded higher last session on Wall Street, up 0.87% to $0.50.
According to the data, Akari Therapeutics Plc (NASDAQ:AKTX) has 2 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $1.50, we find $2.75. Given the previous closing price of $0.49, this indicates a potential upside of 461.22 percent. AKTX stock price is now -4.55% away from the 50-day moving average and -42.03% away from the 200-day moving average. The market capitalization of the company currently stands at $37.62M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 0 analysts have issued a hold rating and 2 have given it a buy rating. Brokers who have rated the stock have averaged $2.75 as their price target over the next twelve months.
With the price target enhanced from $2.50 to $3, B. Riley FBR Upgraded its rating from Neutral to Buy for Akari Therapeutics Plc (NASDAQ: AKTX). On February 08, 2018, B. Riley FBR Inc. recently initiated its ‘Neutral’ rating on the stock quoting a target price of $3, while ‘William Blair’ rates the stock as ‘Outperform’.
A total of 3.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AKTX stock. A new stake in Akari Therapeutics Plc shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $2,124,000. SABBY MANAGEMENT, LLC invested $2,031,000 in shares of AKTX during the first quarter. In the first quarter, HAVERFORD TRUST CO acquired a new stake in Akari Therapeutics Plc valued at approximately $10,000. In total, there are 15 active investors with 13.70% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $0.5000 for Akari Therapeutics Plc (NASDAQ: AKTX). During the past 12 months, Akari Therapeutics Plc has had a low of $0.38 and a high of $1.61. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.50, and a quick ratio of 3.50. The fifty day moving average price for AKTX is $0.5186 and a two-hundred day moving average price translates $0.8539 for the stock.
The latest earnings results from Akari Therapeutics Plc (NASDAQ: AKTX) was released for Jun, 2022.
Akari Therapeutics Plc(AKTX) Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
